• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine

tetano

Editor, Senior Moderator
Vaccine. 2019 Aug 31. pii: S0264-410X(19)31138-7. doi: 10.1016/j.vaccine.2019.08.062. [Epub ahead of print]
[h=1]Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine.[/h] Bar-Peled Y[SUP]1[/SUP], Huang J[SUP]2[/SUP], Nu?ez IA[SUP]2[/SUP], Pierce SR[SUP]1[/SUP], Ecker JW[SUP]1[/SUP], Ross TM[SUP]2[/SUP], Mousa JJ[SUP]3[/SUP].
[h=3]Author information[/h] 1 Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States. 2 Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States. 3 Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States. Electronic address: jarrod.mousa@uga.edu.

[h=3]Abstract[/h] Influenza A virus is a leading cause of death worldwide. Viruses of the H5 subtype have the potential to induce high mortality, and no vaccines are currently available to protect against H5 influenza viruses in the event of an outbreak. Experimental vaccination with one clade 2 virus does not protect against other subclades. The computationally optimized broadly reactive (COBRA) methodology was previously used to generate a H5 hemagglutinin (HA) antigen (COBRA2) that elicited increased serological breadth against multiple clade 2 H5N1 influenza viruses. In this report, we structurally and antigenically characterized the COBRA2 HA antigen. We examined the biochemical characteristics of the COBRA2 protein and determined the protein is correctly cleaved, properly folded into a trimeric structure, and antigenically correct by probing with HA head- and stem-specific monoclonal antibodies (mAbs). We further probed the antigenicity by examining binding of a panel of H5 mouse mAbs to the COBRA2 antigen, as well as several other HA antigens. We determined the X-ray crystal structure of the COBRA2 HA antigen to 2.8 ? and the protein was observed to be in the expected trimeric form. The COBRA2 HA was structurally similar to the naturally occurring H5 HA antigens and suggests the protein folds similar to known HA structures. Overall, our data allow us to formulate a hypothesis on the mechanism of increased breadth due to vaccination with the COBRA2 HA antigen, which is that the protein incorporates antigenic sites from numerous HA antigens, and elicits mAbs with limited breadth, but with diversity in targeted antigenic sites.
Copyright ? 2019 Elsevier Ltd. All rights reserved.


[h=4]KEYWORDS:[/h] Antibody; Hemagglutinin; Influenza; Vaccine

PMID: 31481254 DOI: 10.1016/j.vaccine.2019.08.062
 
Back
Top Bottom